1. Estrogen Receptor α Regulates Metabolic-Associated Fatty Liver Disease by Targeting NLRP3–GSDMD Axis-Mediated Hepatocyte Pyroptosis
- Author
-
Yan Luo, Zhihui Tang, Chenchen Ding, Liping Yan, Lei Xu, Yuting Wu, Mengcong Li, Xiaona Gao, Wentao Fan, Suquan Song, Lei Tan, Zhangshan Gao, and Shuhui Liu
- Subjects
Inflammasomes ,Estrogen receptor ,Genistein ,Mice ,chemistry.chemical_compound ,NLR Family, Pyrin Domain-Containing 3 Protein ,Pyroptosis ,medicine ,Animals ,Receptor ,Liver injury ,Fatty liver ,Estrogen Receptor alpha ,Intracellular Signaling Peptides and Proteins ,Inflammasome ,General Chemistry ,Phosphate-Binding Proteins ,medicine.disease ,Cell biology ,medicine.anatomical_structure ,chemistry ,Hepatocyte ,Hepatocytes ,General Agricultural and Biological Sciences ,medicine.drug - Abstract
Metabolic-associated fatty liver disease (MAFLD) is currently one of the main causes of chronic liver disease, but its potential mechanism remains unclear. This study proved that estrogen receptor α (ERα) could negatively control hepatocyte pyroptosis by inhibiting NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation, gasdermin D (GSDMD)-N generation, propidium iodide (PI) uptake, lactate dehydrogenase (LDH) release, and pro-inflammatory cytokine (IL-1β and IL-18) release. Furthermore, inhibition of pyroptosis ameliorated ERα deletion-induced metabolic dysfunction, insulin resistance, and liver injury. Mechanistically, ERα was confirmed to inhibit pyroptosis by directly interacting with GSDMD, and GSDMD blockade reversed the ERα inhibition-induced pyroptosis and improved lipid accumulation in hepatocytes. Notably, the treatment of wild-type (WT) mice with genistein, a phytoestrogen, could attenuate high-fat diet (HFD)-induced liver lipid steatosis and inhibit NLRP3-GSDMD-mediated pyroptosis. Results provide new insights into the underlying mechanism of pyroptosis regulation and uncover the potential treatment target of MAFLD.
- Published
- 2021